Document Detail


The prognosis of noncutaneous, nonlymphomatous malignancy after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry.
MedLine Citation:
PMID:  20970595     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
INTRODUCTION: Malignancy is a major complication in the management of solid organ transplant patients. Skin cancers show a better prognosis than other neoplasms, but not all others are equal: Ideally, patient management must take into account the natural history of each type of cancer in relation to the transplanted organs. We sought to determine the prognosis of various groups of noncutaneous nonlymphomatous (NCNL) cancers after heart transplantation (HT).
METHODS: We retrospectively analyzed the records of the Spanish Post-Heart-Transplant Tumour Registry, which collects data on posttransplant tumors in all patients who have undergone HT in Spain since 1984. Data were included in the study up to December 2008. We considered only the first NCNL post-HT tumors.
RESULTS: Of 4359 patients, 375 developed an NCNL cancer. The most frequent were cancers of the lung (n=97; 25.9%); gastrointestinal tract (n=52; 13.9%); prostate gland (n=47; 12.5%; 14.0% of men), bladder (n=32; 8.5%), liver (n=14; 3.7%), and pharynx (n=14; 3.7%), as well as Kaposi's sarcoma (n=11; 2.9%). The corresponding Kaplan-Meier survival curves differed significantly (P<.0001; log-rank test), with respective survival rates of 47%, 72%, 91%, 73%, 36%, 64%, and 73% at 1 year versus 26%, 62%, 89%, 56%, 21%, 64%, and 73% at 2 years; and 15%, 51%, 77%, 42%, 21%, 64%, and 52% at 5 years post-diagnosis, respectively.
CONCLUSION: Mortality among HT patients with post-HT NCNL solid organ cancers was highest for cancers of the liver or lung (79%-85% at 5 years), and lowest for prostate cancer (23%).
Authors:
M G Crespo-Leiro; L A Alonso-Pulpón; A Villa-Arranz; V Brossa-Loidi; L Almenar-Bonet; F González-Vilchez; J F Delgado-Jiménez; N Manito-Lorite; B Díaz-Molina; G Rábago; J M Arizón-del Prado; N Romero-Rodríguez; V Brossa; T Blasco-Peiró; D Pascual-Figal; L de la Fuente-Galán; J Muñiz-García
Related Documents :
18393325 - Improved survival time: what can survival cure models tell us about population-based su...
25356865 - Triggering necroptosis in cisplatin and iap antagonist-resistant ovarian carcinoma.
20081585 - Clinical news.
3805235 - Black/white differences in bladder cancer patient survival.
25237375 - Lung cancer screening: subsequent evidences of national lung screening trial.
2737155 - Effects of progestins, estrogens, and antihormones on growth and lactate dehydrogenase ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Transplantation proceedings     Volume:  42     ISSN:  1873-2623     ISO Abbreviation:  Transplant. Proc.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0243532     Medline TA:  Transplant Proc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3011-3     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Inc. All rights reserved.
Affiliation:
Servicio de Cardiología, H. A Coruña, Hospital Universitario A Coruña, La Coruña, Spain. Marisa.Crespo.Leiro@sergas.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Long-term outcome in heart transplant patients with pretransplant malignancies.
Next Document:  Efficacy and tolerance of different types of prophylaxis for prevention of early aspergillosis after...